• Exchange: Stockholm
  • Sector: Health Care
  • Industry: Biotech & Pharma
  • Sub-Industry: Specialty Pharmaceuticals


45.5000 SEK 0.5000 1.09%

As of 05:10:35 ET on 07/14/2014.

Snapshot for Probi AB (PROB)

Open: 45.0000 Day's Range: 44.8000 - 45.5000 Volume: 2,445
Previous Close: 46.0000 52wk Range: 37.0000 - 53.0000 1-Yr Rtn: +13.53%

Stock Chart for PROB

No chart data available.
  • PROB:SS 45.5000
  • 1D
  • 1M
  • 1Y
Interactive PROB Chart

Previous Close

No chart data available.
Interactive Chart
  • 1D
  • 1W
  • 1M
  • YTD
  • 1Y
  • 3Y
  • 5Y
Recently Viewed Symbols
Save as Watchlist
Saving as watchlist...

Key Statistics for PROB

Current P/E Ratio (ttm) 27.3350
Estimated P/E(12/2014) 23.1552
Relative P/E vs. OMX 1.6349
Earnings Per Share (SEK) (ttm) 1.6645
Est. EPS (SEK) (12/2014) 1.9650
Est. PEG Ratio -
Market Cap (M SEK) 426.12
Shares Outstanding (M) 9.37
30 Day Average Volume 7,201
Price/Book (mrq) 3.1413
Price/Sale (ttm) 4.0188
Dividend Indicated Gross Yield 1.65%
Cash Dividend (SEK) 0.7500
Dividend Ex-Date 04/30/2014
5 Year Dividend Growth -
Next Earnings Announcement 08/19/2014
mrq = Most Recent Quarter; ttm = Trailing Twelve Months

Income Statement for PROB

  • Revenue
  • Net Income (M/SEK)
  • Profit Margin (%)

Company Profile & Key Executives for PROB

Probi AB carries out research and development in probiotics. The Company has three main research areas: surgery and medicine, foodstuff technology, and microbiology. Probi has developed the fruit drink ProViva, containing active bioculture intended to counteract harmful bacteria and strengthen the immune system. The Company also develops animal feed. Probi markets internationally.

Peter NaehlstedtChief Executive OfficerNiklas BrandtChief Financial Officer
Niklas BjaerumVP:Marketing & SalesGun Britt FranssonVP:Research&Development
More Company Profile & Key Executives for PROB

Quotes delayed, except where indicated otherwise. All prices in local currency. Time is ET.

Sponsored Link
Sponsored Links
sec ||= nil